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FTO biology and obesity: why do a billion of us weigh 3 kg 
more?
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Metabolic Research Labs, Institute of Metabolic Science, Addenbrooke’s Hospital, University of Cambridge, Cambridge, UK
Few would dispute that the current obesity epidemic has been driven by lifestyle and 
environmental changes. However, it is clear that individuals respond differently to these 
“obesigenic” changes and this variation in response has a strong genetic element. Genome-
wide association studies have revealed that single nucleotide polymorphisms in Fat mass and 
obesity-associated transcript (FTO) are robustly associated with body mass index and obesity. 
Although the effect of these risk alleles are modest, with heterozygous and homozygous 
carriers weighing approximately 1.5 and 3 kg more respectively, there are an estimated one 
billion homozygous carriers in the world, spanning multiple different ethnicities and populations. 
Yet despite its broad impact, the biological function of FTO, particularly its role in controlling 
energy balance, remains unknown. Although the study of severe Mendelian obesity has been 
invaluable in illuminating critical pathways controlling food intake, the major burden of disease 
is carried by those of us with “common obesity, ” which to date has resisted yielding meaningful 
biological insights. FTO has at last given us a handle on a huge, worldwide, common problem. 
In this review, we focus on the available genetic and in vivo evidence to date that implicates 
FTO in the control of energy balance.
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of most of its components by monogenic defects, either in humans 
or mice, results in severe early onset obesity (Vaisse et al., 1998; 
Yeo et al., 1998; Stutzmann et al., 2007). In humans however, these 
monogenic causes of severe obesity are extremely rare. In contrast 
to the Mendelian obesity syndromes, common obesity is likely to 
have a “polygenic” etiology, with multiple variations each having a 
subtle effect. It is therefore unsurprising that conventional candi-
date gene analysis either failed in reliably detecting novel variants 
or validating these minor gene defects.
It was only within the past few years that the required technology 
to interrogate hundreds of thousands (now more than a million) 
single nucleotide polymorphisms (SNPs) in parallel was developed. 
These technologies, which allow for genome-wide association stud-
ies (GWAS), coupled with unprecedented international collabora-
tions resulting in the collection of increasing large study cohorts, 
have become extremely powerful for detecting common genetic 
variants associated with complex disorders like obesity. Thus in 
many ways, the rapidly evolving environment coupled with the 
emergence of new technologies have served to magnify previously 
subtle genetic susceptibility.
Discovery of fTo from GWAs
In 2007, a T2D GWAS identified multiple SNPs in the first intron of 
a gene called Fat mass and obesity-related transcript (FTO) associated 
with disease. However the association between these FTO SNPs and 
T2D disappeared after adjustment for BMI, suggesting that these 
SNPs were actually associated with BMI, with increased weight 
being a risk factor for T2D. Confirmation of this association with 
BMI was replicated in 13 independent cohorts including a total of 
38,759 participants (Frayling et al., 2007). Subsequently and in close 
inTroDucTion
Obesity is a severe problem facing most developed nations and 
many other emerging economies (Zimmet et al., 2001). The World 
Health Organization estimates there will be more than 2 billion 
overweight and 700 million obese adults in the world by 2015, 
and by 2050, 90% of today’s children will be overweight or obese. 
This is a huge drain on the healthcare systems of affected countries 
not because of obesity itself per se, but because of the associated 
increased risk to several unpleasant co-morbidities, including type 
2 diabetes mellitus (T2D), hypertension, cardiovascular diseases, 
and certain forms of cancer (Calle et al., 1999; Katzmarzyk et al., 
2003). In addition, other consequences of being obese often include 
social stigmatization and discrimination.
It is clear that lifestyle and environmental changes that have 
occurred over the past 20 years, including a more convenient sup-
ply of high calorie food and decreased physical activity, underlie 
the etiology of this phenomenon. However, it is also clear that 
genetic factors have a powerful role to play, with different individu-
als responding in different ways to this changing environment. 
In fact, genetic influence plays an important role in individual 
body mass index (BMI) differences, with twin and adoption stud-
ies estimating the heritability of fat mass to be between 40 and 
60% (Raman, 2002). Thus, obesity is determined by interactions 
between individual genetics and environmental factors (Hill and 
Peters, 1998).
Over the past 15 years, studies of Mendelian inherited syndromes 
of obesity in humans, together with the use of monogenic mouse 
models have been invaluable in illuminating critical pathways con-
trolling food intake and body weight. The most well characterized to 
date is the central leptin–melanocortin pathway, where disruption 
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succession, a number of other independent studies encompass-
ing adults and children from several European populations(Dina 
et al., 2007; Scuteri et al., 2007; Peeters et al., 2008; Attaoua et al., 
2009; Gonzalez-Sanchez et al., 2009; Jonsson et al., 2009), as well 
as populations of Asian (Cha et al., 2008; Chang et al., 2008; Hotta 
et al., 2008; Tan et al., 2008), and African ancestries (Grant et al., 
2008; Hennig et al., 2009; Adeyemo et al., 2010; Bollepalli et al., 
2010; Keebler et al., 2010), reported associations of FTO intron 1 
SNPs with obesity-related traits including increased hip circumfer-
ence, waist to hip ratio and body weight. Thus, FTO became the 
first of the post-GWAS obesity genes. In this review, we examine 
the current status of human genetic and rodent model data and 
how these have begun to inform us of the complex biology of FTO 
and its involvement in the control of energy balance.
cArriers of fTo vAriAnTs WeiGh 3 kG heAvier
The  FTO  SNP  rs9939609  has  the  strongest  known  effect  on 
increased BMI, particularly within European populations. Frayling 
et al. (2007) reported that individuals homozygous for the A “risk” 
allele weigh approximately 3 kg more and have a 1.67-fold increased 
risk  of  developing  obesity,  while  heterozygous  carriers  display 
an intermediate weight gain of 1.5 kg. The association between 
rs9939609 and increased BMI/obesity was replicated and confirmed 
in both adults and children in multiple ethnic groups (Al-Attar 
et al., 2008; Andreasen et al., 2008; Karasawa et al., 2010). However 
the allelic frequency of rs9939609 is different across ethnic groups, 
for example close to 60% of most European populations carrying 
one or more copy of the A “risk” allele as compared to 17% in some 
Asian populations (Song et al., 2008). Despite the variation in fre-
quency, the modest effect size of 3 kg remains consistent regardless 
of ethnicity. With an estimated 1 billion homozygous carriers in the 
world, FTO is clearly influencing in some way the body weight of a 
significant proportion of the world’s population (Leibel, 2008).
As regulation of body weight is of course a balance between energy 
intake and energy expenditure, many of the subsequent studies have 
examined the influence of FTO variants on measures of appetite, food 
intake, or energy expenditure (Hakanen et al., 2009; Haupt et al., 
2009). Subjects homozygous for the A risk allele of rs9939609 eat 
significantly more (Speakman et al., 2008; Wardle et al., 2009), have 
reduced satiety (Wardle et al., 2008; den Hoed et al., 2009; Tanofsky-
Kraff et al., 2009), prefer higher caloric food and have a higher fat mass 
(Cecil et al., 2008; Timpson et al., 2008) than subjects homozygous for 
the T allele. The association of FTO SNPs with energy intake are seen 
even in small sample sizes (n = 150), which lack the required power 
to identify the association with small increases in BMI (Speakman 
et al., 2008). Thus, based on the weight of evidence to date, FTO risk 
alleles are unequivocally associated with increased food intake and 
appetitive behavior. In contrast, the association with the other half 
of the energy balance equation is less clear. Certainly, FTO SNPs are 
not associated with reduced energy expenditure (Speakman et al., 
2008; Goossens et al., 2009; Haupt et al., 2009) or physical activity 
(Jonsson et al., 2009). However, there is some evidence showing an 
association with increased energy expenditure, as well as increased 
physical activity levels (Jonsson and Franks, 2009).
Association of FTO SNPs with other metabolic traits includ-
ing higher plasma levels of C-reactive protein (CRP; Fisher et al., 
2009; Sun et al., 2010) and an increased degree of insulin resistance 
(Jacobsson et al., 2008), independent of their association with BMI 
have also been reported. However the results are not consistent, 
with other researchers finding that these associations disappear 
after correction for BMI (Legry et al., 2009).
FTO or RpgRip1l?
Powerful though it has been, it is easy to forget that GWAS is a 
gene agnostic approach. SNPs reaching the appropriate statistical 
threshold for a given phenotype or disease can appear anywhere in 
the genome, within, near or far away from any coding sequence. The 
current assumption that the closest coding region, which is some-
times hundreds of kilobases away, is the likely candidate is perhaps a 
reasonable first guess, but not necessarily true (Cantor et al., 2010). 
In this instance, the “FTO” risk alleles are actually located in the first 
intron of the FTO gene. However, they are also very close to the 
transcriptional start site of RPGRIP1L (human ortholog of mouse 
Ftm), which is adjacent to and coded for on the opposite DNA strand 
to FTO (Stratigopoulos et al., 2008), as shown in Figure 1. So why, 
in this situation, was FTO invoked, instead of RPGRIP1L?
Rpgrip1l is previously known to localize in the primary cilia 
and centrosomes of ciliated cells (Arts et al., 2007). The protein 
binds to nephrocystin-4 and is involved in mechanisms including 
programmed cell death, craniofacial development, patterning of 
the limbs, and formation of the left–right axis (Tokue et al., 2009). 
Crucially, defects in human RPGRIP1L exist and cause two rare 
genetic disorders; Joubert syndrome type 7 (JBTS) and Meckel 
syndrome type 5 (MKS5). JBTS is caused by homozygous loss-of-
function missense mutations in RPGRIP1L, and presents clinically 
with a peculiar cerebellar and brainstem malformation known as 
the “molar tooth sign” (MTS) and renal failure (Brancati et al., 
2008; Tokue et al., 2009). MKS5 is a far more severe variant of 
the disease which results from non-sense or frameshift mutations 
in RPGRIP1L, thereby resulting in a complete loss-of-function 
of the protein (Delous et al., 2007). The patients do not present 
with any obvious obesity-related phenotypes, with the caveat that 
any potential “lean” phenotype is difficult to ascertain in a healthy 
individual, let alone someone who is severely ill. Deletion of the 
mouse ortholog Rpgrip1l (Ftm) recapitulates the cerebral, renal, 
and hepatic defects seen in the patients. Therefore it is less likely 
that Rpgrip1l, in of itself, is related to the BMI phenotype.
However, there is evidence for possible co-regulatory mecha-
nisms between FTO and RPGRIP1L. Stratigopoulos et al. (2008) 
report an overlapping regulatory region within intron 1 of FTO 
that contains at least two putative transcription factor binding sites 
(CUTL1), one of which overlaps with another obesity-associated 
SNP (rs8050136). The group reported a reduced expression level of 
both FTO and RPGRIP1L when the CUTL1 site is knocked-down 
human fibroblasts, however the mechanism of this phenomenon 
remains to be determined (Stratigopoulos et al., 2008, 2011). They 
speculate that the association between FTO SNPs and body weight 
regulation is mediated through changing the expression of both 
FTO and RPGRIP1L.
WhAT is fTo?
Fto was originally identified in 1999 as one of six contiguous genes 
in a naturally occurring 1.6 Mb deletion on chromosome 8 in a 
mouse model known as fused toes (Ft). Homozygous Ft mutants are www.frontiersin.org  February 2011  | Volume 2  | Article 4  |  3
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substrate preference for methylated RNA over DNA (Jia et al., 2008). 
These in vitro studies suggest that FTO’s physiological role could be 
linked with nucleic acid repair or modification. In addition, FTO is 
present in the cellular nucleus (Gerken et al., 2007), which supports 
its functional involvement in nucleic acid demethylation. However 
we still do not know the endogenous substrates of FTO and how 
this demethylation activity of FTO is linked to human obesity.
Recently, the X-ray crystallography structure of FTO provided a 
basis for the study of structure–function relationships. The protein 
is composed of two domains: an N-terminal domain carrying a cata-
lytic core and a C-terminal domain of unknown structural homol-
ogy as shown in Figure 2 (Han et al., 2010). In the catalytic domain 
are five obligate amino acid residues found in all members of this 
enzyme superfamily; two residues, a histidine (H) and an aspartic 
acid (D), required for binding Fe(II); and three residues, an H and 
two arginines (R) separated by six amino acids, required for 2-OG 
binding. Structural based sequence alignment showed that FTO has 
an extra region, referred to as Loop 1, which is highly conserved 
among FTOs from different species, but is absent from AlkB and ABH 
proteins. The crystal structure reveals that Loop 1 sterically hinders 
the unmethylated strand of dsDNA/RNA from gaining access to the 
substrate-binding site, explaining why FTO has a substrate preference 
for single-stranded nucleic acid (Han et al., 2010).
humAn fTo Deficiency
There are several examples in metabolic disease where common 
variants close to a particular gene are associated with alterations in 
risk of common phenotypes such as fat mass or risk of obesity, while 
rare loss or gain of function mutations in the same gene are associ-
ated with a more severe version of the same metabolic phenotype, 
e.g., MCR4 (Vaisse et al., 1998; Yeo et al., 1998; Geller et al., 2004; 
Stutzmann et al., 2007; Chambers et al., 2008; Loos et al., 2008), 
POMC (Krude et al., 1998; Challis et al., 2002), BDNF (Gray et al., 
2006; Han et al., 2008; Thorleifsson et al., 2009), and PCSK1 (Jackson 
et al., 1997; Benzinou et al., 2008). When information is available 
from both types of variants, clarity of mechanistic understanding 
is greatly enhanced. Can the same thing be said for FTO?
In 2009, we in collaboration with others, reported a large con-
sanguineous family of Palestinian Arab origin with nine members 
affected by a previously unknown polymalformation syndrome, all of 
embryonic lethal and display neural tube defects, whereas hetero-
zygous mice have fused toes, and are not obese. In addition to Fto, 
the other five genes are Irx3, Irx5, Irx6, Fts, and the aforementioned 
Rpgrip1 (van der Hoeven et al., 1994; Peters et al., 1999, 2002). The 
genomic region adjacent to FTO together with the relative location 
of these other genes are shown in Figure 1. Irx3, Irx5, and Irx6 
belong to the Iroquois-class of homeodomain proteins, which are 
transcriptional factors involved in SHH-dependent neural pattern-
ing (Briscoe et al., 2000). Fts encodes a Hook-interacting protein 
of unknown function but is predicted by sequence similarity to be 
involved in vesicle transport (Okazaki et al., 2003). None of these 
other genes have been implicated in any obese phenotype.
FTO is a large gene of nine exons spanning more than 400 kb 
on chromosome 16 in humans. All the SNPs identified so far are 
located in the first and largest intron of the gene, a region where 
the sequence is strongly conserved across species (Loos et al., 2008). 
Evolutionarily, FTO is found only in vertebrates and marine algae, 
and is absent from all invertebrates, fungi, green plants, or bacteria, 
suggesting that the gene was present 450 million years ago and has 
undergone horizontal gene transfer (Robbens et al., 2008).
FTO is widely expressed in fetal and adult tissues in humans, 
mice, and rats, with the highest expression in the brain (Vaisse 
et al., 1998; Frayling et al., 2007; Stutzmann et al., 2007). Within 
the brain, Fto expression is relatively high in a number of hypotha-
lamic nuclei: arcuate (ARC), paraventricular (PVN), dorsomedial 
(DMN), and ventromedial (VMN) nuclei, where control of energy 
homeostasis is centered (Gerken et al., 2007; Fredriksson et al., 
2008). Soon after the first report of FTO, we and others used a 
bioinformatics approach to show that human FTO has the highest 
sequence similarity with the E. coli DNA repair protein AlkB and 
its mammalian homologues ABH2 and 3, which all belong to the 
family of Fe
2+ and 2-oxoglutarate (2-OG)-dependent dioxygenases 
(Gerken et al., 2007). Members of the family are involved in vari-
ous cellular processes including DNA repair, fatty acid metabolism 
and post-translational modifications. Gerken et al. (2007) showed 
that in vitro, FTO catalyzes the demethylation of 3-meT in single-
stranded DNA in the presence of Fe2+ and 2-OG, with concomitant 
production of succinate, formaldehyde, and carbon dioxide. A sub-
sequent study reported FTO has a slight preference for 3-meU in 
single-stranded RNA, than for 3-meT, suggesting that FTO has a 
FiGurE 1 | Genomic organization of FTO and its neighboring genes (not drawn to scale). The FTO gene contains nine exons which are depicted in blue 
rectangles and the most replicated FTO SNP rs9939609 is found in intron 1 of the gene. CUTL1 binding site overlaps with the FTO SNP rs8050136 (Stratigopoulos 
et al., 2011).Frontiers in Endocrinology  | Cellular Endocrinology    February 2011  | Volume 2  | Article 4  |  4
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regulatory role, either to up- or down-regulate FTO expression. In 
addition, it is also possible that the SNPs could be involved in post-
transcriptional modifications, which could result with various FTO 
splice variants and isoforms of different functions.
Lessons from fTo roDenT moDeLs of fTo
Mouse models of Fto deficiency, although far from being straight-
forward, have been more helpful in illuminating a role for FTO 
energy balance. Phenotypic characteristics of the five recent Fto 
rodent models are summarized in Table 1.
GLobAL fTo knockouT
Mice homozygous for a targeted deletion in Fto display a complex 
phenotype (Fischer et al., 2009). They are postnatally growth retarded 
with decreased fat and lean body mass, and although are born with a 
normal body weight and at the expected Mendelian ratio, display 50% 
lethality by the time of weaning. That they are born normally implies 
that implantation and embryonic development are not grossly affected. 
The cause of the postnatal lethality is still unknown, however it appears 
that a complete ablation of Fto in mice causes retarded postnatal devel-
opment, consistent with FTO deficiency in humans, supporting the 
hypothesis that Fto is involved in normal body development. They also 
suffer from a curious and as yet unexplained reduction in ambulatory 
movement. A detailed study of the organs from these Fto−/− mice has 
yet to be reported and could prove informative.
In support of the human data showing that FTO risk SNPs 
strongly correlate with increased food intake, Fto−/− mice appear 
to display hyperphagia and increased energy expenditure when cor-
rected for lean body mass. The authors suggested that the increase in 
energy expenditure occurs in the presence of a higher sympathetic 
activity, which is demonstrated by a higher circulating concentra-
tion of adrenaline in the Fto−/− mice.
Resonant with the studies exploring the link between the risk 
alleles and metabolic rate in humans, the observation that Fto null 
mice have increased energy expenditure has not been without con-
troversy. In fact, it has ignited a broader debate within the metabolic 
field about the methodologies underlying the general measurement 
of energy expenditure in rodents.
Since the hypothalamus is important for control of energy 
balance, and it is a region where Fto is highly expressed, Fischer 
et al. (2009) then went on to examine whether the hyperphagic 
whom were homozygous for an arginine to glutamine change at posi-
tion 316 (R316Q) in FTO. Unfortunately for the affected individuals, 
because R316 is one of the obligate residues required for binding of 
2-OG, the R316Q mutation completely abolishes its demethylase 
activity. The syndromic characteristics observed in the affected indi-
viduals include postnatal growth retardation, microcephaly, severe 
functional brain deficits, facial dysmorphism, cardiac abnormalities, 
and cleft palate. Tragically, the severity of the phenotype was such that 
all affected children died within the first 30 months of life. Although 
the heterozygous carriers within this family did not have their clinical 
phenotype specifically studied, no overt obesity-related phenotypes 
were reported (Boissel et al., 2009).
In another study, we screened the coding regions of FTO in 1400 
lean and morbidly obese individuals to determine if there was an 
increased burden of non-synonymous variants in either cohort. In 
short, the answer was no. However, we did identify two novel loss-
of-function FTO mutations; R96H, which occurs in the substrate 
recognition lid and R322Q, the second obligate arginine required 
for 2-OG binding, both of which were found in heterozygous form 
and resulted in complete loss of catalytic activity. Unfortunately, 
these two mutations did nothing to clarify the role of FTO in energy 
balance, as the mutations were each identified twice in both lean 
and obese individuals (Meyre et al., 2010). It is a puzzle that while 
SNPs in intron 1 of FTO are unequivocally associated with obesity 
in multiple populations, it appears that loss of one functional copy 
of FTO in humans is compatible with being either lean or obese.
There is an oddity about the distribution of the mutations 
throughout FTO, which may yet prove relevant. Although non-
synonymous variants elsewhere in the molecule are found equally 
in  obese  and  lean  subjects,  eight  such  variants  found  in  the 
  carboxy-terminus were detected in obese subjects and only two in 
lean (Meyre et al., 2010). It remains to be seen if this clue transpires 
into anything of functional significance. What is clear is FTO seems 
to have a critical, but as yet undetermined role, in the development 
of several major organ systems, including the central nervous and 
cardiovascular systems.
At this point, it is worth noting that to date, we do not know if or 
how the FTO risk alleles are influencing the FTO protein. Considering 
the intronic location of all the FTO obesity-related SNPs (spanning 
across ∼40 kb), they are unlikely to cause functional mutations. 
Instead, the SNPs are more likely to be playing a transcriptional 
FiGurE 2 | FTO Crystal Structure. (A) Overall structure of FTO protein. The 
C-terminal with an unknown structural homology, and the N-terminal domain 
that contains the catalytic core, are colored in cyan and yellow respectively. 
(B) FTO’s catalytic site is shown, with its bound substrates: 3-meT and 
2-oxoglutarate (2-OG) highlighted in green. The extra loop 1 from FTO that 
physically hinder the entrance of dsDNA/RNA is in red. (C) Residues that cause 
a compete loss-of-function of FTO: R316 and R322 that are required for 2-OG 
binding, and R96 that occurs in the substrate recognition lid, are shown in blue. 
The molecular graphics were generated using PyMOL (Version 1.1r1, 
Schrödinger, LLC).www.frontiersin.org  February 2011  | Volume 2  | Article 4  |  5
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weight and fat mass when they were fed either chow or a HFD. 
However despite the significant increase in fat mass, lean mass 
was not found to be changed in mice overexpressing Fto (with the 
exception of the female Fto-4 mice), leading the authors to suggest 
that overexpression of Fto has a positive influence on fat-to-lean 
tissue mass ratio in these mice. There was no significant change in 
either energy expenditure or physical activity.
Although the increase in weight with the overexpression of Fto 
seems consistent with Fto deficiency resulting in a “lean” phenotype, 
the increase in food intake seen in these mice is not. The authors 
go on to look at circulating leptin concentrations, and find that, 
curiously, at the age of 8 weeks, both Fto-3 and Fto-4 mice had 
reduced leptin levels after a 16-h overnight fast compared to wild-
type controls. It is fascinating that this phenomenon occurs, keeping 
in mind that these are obese mice, whose normal response would 
be to have increased circulating leptin, reflecting their increased 
fat mass. The authors comment that the hyperphagic phenotype is 
possibly due to an Fto dependent reduction of leptin, although no 
mechanism is invoked. However at the age of 20 weeks, circulating 
leptin levels returned to levels commensurate with the increased fat 
mass resulting from the hyperphagia seen in the Fto overexpressing 
mice. The observation seems to have contradicted their regression 
analysis that showed a positive correlation between leptin level and 
fat mass content.
fTo in The hypoThALAmus moDuLATes fooD inTAke
As discussed above, FTO is found ubiquitously in many tissues in 
human, mice, and rats, but is highest expressed in the brain, espe-
cially in feeding-related nuclei in the hypothalamus where control of 
energy homeostasis is centered (Gerken et al., 2007; Fredriksson et al., 
2008). Given the fact the Fto is highly expressed in a multiple feeding-
related nuclei in the hypothalamus, it was interesting to ask whether 
Fto mRNA levels are nutritionally regulated. Indeed, expression of Fto 
in the ARC is bi-directionally regulated as a function of nutritional 
status; decreasing following a 48-h fast (Fredriksson et al., 2008) and 
increasing after 10 weeks of exposure to a HFD (Tung et al., 2010). 
Since fasting, a strong stimulus to eat, reduces Fto mRNA levels in the 
ARC, if Fto was having a direct action on the control of energy intake 
one would predict that reducing its expression would recapitulate the 
fasting state, thereby resulting in an increase in food intake. This does 
  phenotype of Fto−/− mice is caused by hypothalamic functional 
defects. However neither abnormal hypothalamic development 
nor  changes  in  expression  levels  of  feeding-related  neuropep-
tides in the arcuate nucleus of the hypothalamus (ARC) of adult 
Fto−/− mice were found. The most crucial piece of evidence in 
this report supporting a role for Fto in energy balance is that the 
Fto+/− mice, who are not growth retarded, appear to be resistant 
to high-fat diet (HFD) induced obesity, when compared with their 
wild-type littermates.
As discussed above, since Fto lies in close proximity to Rpgrip1l, 
the  authors  checked  for  Rpgrip1l  mRNA  expression  levels  in 
the  Fto−/−  and  Fto+/−  mice  and  found  no  changes,  arguing 
against the co-regulation of both genes playing a role in body 
weight regulation.
enu inDuceD fTo muTATion
Another mouse model that harbors a global Fto mutation I367F 
subsequently followed (Church et al., 2009). The group reported 
that an N-ethyl-N-nitrosourea (ENU) mutagenesis induced point 
mutation in Fto (I367F) resulted in a partial loss-of-function, a 
60% drop in catalytic activity, when compared to wild-type control. 
Both FtoI367F homozygous and heterozygous male mice had reduced 
body weight compared to their wild-type littermates from 12 weeks 
onward, and presented with a reduction of fat mass, but not lean 
mass. Given the fact that no difference in food intake and physical 
activity was found between these Fto mutant male mice and their 
control littermates, the authors suggested that the reduction of their 
body weight is a consequence of an increase in resting metabolic 
rate. FtoI367F mice also have a higher level of glucagon compared to 
wild-type controls, suggesting they may have an increased sympa-
thetic activity. Thus, FtoI367F mice resemble Fto−/− mice in many 
areas, except with a milder phenotype and the absence of devel-
opmental problems.
mice overexpressinG fTo
More recently, Church et al. (2010) have generated a mouse model 
that carries one or two additional copies of Fto (Fto-3 for three 
additional copies; one plus the two endogenous copies and Fto-4 
for two additional copies). Mice overexpressing Fto showed a dra-
matic increase in food intake resulting in a marked increase in body 
Table 1 | Summary of phenotypes from the five different Fto rodent models.
  rodent models of Fto  Body weight  Body composition  Energy  Energy    
        uptake  expenditure
Only in hOmOzyGOuS KnOCKOuTS
Global Fto knockout  Fischer et al. (2009)  Mice  Fto−/−  ↓  ↓Lean and fat mass  ↑  ↑
BOTh in hOmOzyGOuS And hETErOzyGOuS muTAnTS
Global Fto mutation  Church et al. (2009)  Mice  FtoI367F  ↓  ↓Fat mass; no change  No change  ↑
          in lean mass
Global Fto overexpression  Church et al. (2010)  Mice  Fto-3  ↑  ↑Fat mass; no change  ↑  No change
      Fto-4    in lean mass
ARC-specific Fto manipulation  Tung et al. (2010)  Rats  Ftooverexpress  No change  No data  ↓  No data
    Rats  Ftoknockdown  No change  No data  ↑  No data
Only in hOmOzyGOuS KnOCKOuTS
Brain-specific Fto knockout  Gao et al. (2010)  Mice  Fto−/−  ↓  ↓Lean and fat mass  ↑  ↑Frontiers in Endocrinology  | Cellular Endocrinology    February 2011  | Volume 2  | Article 4  |  6
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brAin-specific FTO ko
Central nervous system (CNS) specific Fto deleted mice have now 
been generated by Gao et al. (2010). Surprisingly, these brain-spe-
cific Fto deficient mice recapitulate the phenotype of the whole-
body knockouts, although this is yet to be exhaustively examined. 
This suggests that much of Fto’s function, including its link to the 
regulation of energy homeostasis (and in keeping with the observa-
tions by Tung et al. (2010), is mediated in the brain.
In the past 3 years, 23 other genetic loci have been identified 
to be associated with increased BMI from independent GWAS in 
adults. Most of the presumed candidate in these loci, as we have 
discussed here with FTO, are also highly expressed or are known to 
act in the CNS, emphasizing, as in rare monogenic forms of obes-
ity, the role of the CNS in predisposition to obesity (Willer et al., 
2009). Perhaps there is some truth to the statement that “obesity 
is all in your head” after all!
concLusion
FTO is the first and the most robust gene identified to be associated 
with increased BMI in humans in the post-GWAS era. Yet despite its 
broad impact, FTO’s biological function, particularly the molecu-
lar mechanisms underlying its role in controlling energy balance, 
remains unknown. The major burden of disease is carried by those 
of us with “common obesity,” which to date has resisted yielding 
meaningful biological insights. FTO has at last given us a handle on 
a huge, worldwide, common problem and demands exploration. 
Understanding the biology of FTO could uncover novel pathways 
and mechanisms controlling energy balance, revealing new thera-
peutic targets in our battle against obesity.
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